
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June 2023

Commission File Number: 001-41562

NewAmsterdam Pharma Company N.V.
(Exact name of registrant as specified in its charter)

**Gooimeer 2-35
1411 DC Naarden
The Netherlands**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

On June 20, 2023, NewAmsterdam Pharma Company N.V. (the “Company”) held the Company’s 2023 annual general meeting of shareholders (the “Annual General Meeting”). Of the total of 82,140,286 of the Company’s ordinary shares issued, outstanding and eligible to vote as of the record date of May 23, 2023, a quorum of 51,298,022 ordinary shares, or approximately 62.45%, voted in person or by proxy at the Annual General Meeting.

The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

Agenda Item 3. The Company’s shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2022. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,287,223	10,598	201	—

Agenda Item 4. The Company’s shareholders approved the discharge from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2022. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,286,700	11,162	160	—

Agenda Item 5. The Company’s shareholders approved the appointment of and instruction to Deloitte Accounts B.V. as the external independent auditor for the audit of the Company’s annual accounts for the fiscal year 2023. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,287,647	10,375	0	—

Agenda Item 7. The Company’s shareholders approved the appointment of John William Smither as non-executive director of the Company. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,287,446	10,375	201	—

Agenda Item 8. The Company’s shareholders approved the appointment of Hilde Johanna van der Kamp as non-executive director of the Company. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,287,446	10,375	201	—

Agenda Item 9. The Company's shareholders approved the reappointment of Johannes Jacob Pieter Kastelein as non-executive director of the Company. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,287,446	10,375	201	—

Agenda Item 10. The Company's shareholders approved the reappointment of Hugo Alexander Slootweg as non-executive director of the Company. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,287,720	10,101	201	—

Agenda Item 11. The Company's shareholders approved the reappointment Nicholas Sinclair Downing as non-executive director of the Company. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,287,721	10,100	201	—

Agenda Item 12. The Company's shareholders approved the extension of authorization for the Board to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital. The votes cast were as follows:

For	Against	Abstain	Broker Non-Votes
51,296,878	883	261	—

This Report on Form 6-K shall be deemed to be incorporated by reference into the registrant's Registration Statement Form S-8 (File No. 333-271019).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

June 21, 2023

NewAmsterdam Pharma Company N.V.

By: /s/ Michael Davidson

Name: Michael Davidson

Title: Chief Executive Officer